Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. (setembro de 2015). «Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma». The New England Journal of Medicine. 373 (13): 1207–1219. PMID26308596. doi:10.1056/NEJMoa1506348
Vincent L, Gras L, Ceballos P, Finke J, Passweg J, Harel S, et al. (março de 2022). «Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT». Bone Marrow Transplantation. 57 (3): 499–501. PMID35013536. doi:10.1038/s41409-021-01560-y
Nakagawa R, Onishi Y, Kawajiri A, Onodera K, Furukawa E, Sano S, et al. (agosto de 2019). «Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma». Annals of Hematology. 98 (8): 1999–2001. PMID30824957. doi:10.1007/s00277-019-03645-7
Jain A, Ramasamy K (setembro de 2020). «Evolving Role of Daratumumab: From Backbencher to Frontline Agent». Clinical Lymphoma, Myeloma & Leukemia. 20 (9): 572–587. PMID32331971. doi:10.1016/j.clml.2020.03.010
Chapuy CI, Nicholson RT, Aguad MD, Chapuy B, Laubach JP, Richardson PG, et al. (junho de 2015). «Resolving the daratumumab interference with blood compatibility testing». Transfusion. 55 (6 Pt 2): 1545–1554. PMID25764134. doi:10.1111/trf.13069
Perincheri S, Torres R, Tormey CA, Smith BR, Rinder HM, Siddon AJ (2 de dezembro de 2016). «Daratumumab Interferes with Flow Cytometric Evaluation of Multiple Myeloma». Blood. 128 (22). 5630 páginas. ISSN0006-4971. doi:10.1182/blood.V128.22.5630.5630
Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. (outubro de 2016). «Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma». The New England Journal of Medicine. 375 (14): 1319–1331. PMID27705267. doi:10.1056/NEJMoa1607751
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. (agosto de 2016). «Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma». The New England Journal of Medicine. 375 (8): 754–766. PMID27557302. doi:10.1056/NEJMoa1606038
Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. (setembro de 2015). «Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma». The New England Journal of Medicine. 373 (13): 1207–1219. PMID26308596. doi:10.1056/NEJMoa1506348
Vincent L, Gras L, Ceballos P, Finke J, Passweg J, Harel S, et al. (março de 2022). «Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT». Bone Marrow Transplantation. 57 (3): 499–501. PMID35013536. doi:10.1038/s41409-021-01560-y
Nakagawa R, Onishi Y, Kawajiri A, Onodera K, Furukawa E, Sano S, et al. (agosto de 2019). «Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma». Annals of Hematology. 98 (8): 1999–2001. PMID30824957. doi:10.1007/s00277-019-03645-7
Jain A, Ramasamy K (setembro de 2020). «Evolving Role of Daratumumab: From Backbencher to Frontline Agent». Clinical Lymphoma, Myeloma & Leukemia. 20 (9): 572–587. PMID32331971. doi:10.1016/j.clml.2020.03.010
Chapuy CI, Nicholson RT, Aguad MD, Chapuy B, Laubach JP, Richardson PG, et al. (junho de 2015). «Resolving the daratumumab interference with blood compatibility testing». Transfusion. 55 (6 Pt 2): 1545–1554. PMID25764134. doi:10.1111/trf.13069
Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. (outubro de 2016). «Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma». The New England Journal of Medicine. 375 (14): 1319–1331. PMID27705267. doi:10.1056/NEJMoa1607751
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. (agosto de 2016). «Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma». The New England Journal of Medicine. 375 (8): 754–766. PMID27557302. doi:10.1056/NEJMoa1606038
Perincheri S, Torres R, Tormey CA, Smith BR, Rinder HM, Siddon AJ (2 de dezembro de 2016). «Daratumumab Interferes with Flow Cytometric Evaluation of Multiple Myeloma». Blood. 128 (22). 5630 páginas. ISSN0006-4971. doi:10.1182/blood.V128.22.5630.5630